biotech / news / / The Indian Express
Mazumdar-Shaw, who is now Chairperson of Biocon, said it’s part of the five-year phased transition plan for the company.
Biocon is executing a five-year phased leadership transition as part of its succession plan.
KEY POINTS
- Kiran Mazumdar-Shaw has no children and is succeeded by an external professional rather than family.
- Biocon's R&D pipeline includes over 20 biosimilar assets and GLP-1 peptides.
- Biocon reported Rs 2,242 crore turnover and Rs 609 crore net profit for year ended March 2025.
COMPANIES
Summarized by Newsio from The Indian Express. How we summarize →